Rapid brain tumor classification from sparse epigenomic data.

Although the intraoperative molecular diagnosis of the approximately 100 known brain tumor entities described to date has been a goal of neuropathology for the past decade, achieving this within a clinically relevant timeframe of under 1 h after biopsy collection remains elusive. Advances in third-generation sequencing have brought this goal closer, but established machine learning techniques rely on computationally intensive methods, making them impractical for live diagnostic workflows in clinical applications. Here we present MethyLYZR, a naive Bayesian framework enabling fully tractable, live classification of cancer epigenomes.

Workforce Trends Among Canadian Medical Oncologists and Medical Oncology Trainees over Two Decades.

Understanding oncology health human resources across Canada is critical to the delivery of quality cancer care. Little has been published about the medical oncology (MO) workforce and trainees; this study sought to characterize trends in the MO workforce and explore the relationship between medical oncologists and cancer incidence as a surrogate demand marker. : Publicly available databases from the Canadian Medical Association, the Canadian Institute of Health Information, and the Canadian Post MD Education Registry were utilized to estimate the number, demographics, and regional distribution of practicing MOs and MO trainees between 1994 and 2020.

Reduced wait times for molecular-biomarker testing among patients with advanced lung cancer using parallel sample processing and closed-loop communication: the Continuous Oncopanel and ALK Status Tracking (COAST) Project.

Background: Given how crucial molecular-biomarker testing is to treatment decisions for advanced non-small cell lung cancer (NSCLC), guidelines recommend a turnaround time (TAT) of 14 calendar days from receiving specimen to test result, and 3 days to receive a specimen from outside pathology lab. Current TAT for molecular-biomarker testing in British Columbia (BC), Canada frequently exceeds these recommendations. Thus, we launched a quality improvement (QI) initiative to improve TAT of molecular-biomarker testing.